and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD). † When there were no published studies, we relied on the clinical experience of the panelists, which was designated very-low-quality evidence. ‡ Axial disease is generally treated according to the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for spondyloarthritis (SpA). § Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 Table 5. (Cont'd) Active PsA with predominant enthesitis in treatment-naive patients and despite treatment with an OSM (Table 5 In treatment-naive PsA patients with predominant enthesitis, a TNFi biologic is recommended over an OSM as a